Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) rose more than 25% in early trading and was recently cleared and increased by executives to accelerate the release of its core product, Senapali

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) rose more than 25% in early trading. As of press release, it rose 22.52% to HK$13.82, with a turnover of HK$95.6924 million.

According to the news, since September 7, Yingpai Pharmaceutical has been included in the Hong Kong Stock Connect list. The company believes that being included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect will help further expand the company's investor base and is expected to enhance the trading liquidity of the company's H shares. In addition, Cai Suixiong, the company's executive director and CEO, recently purchased a total of 100,000 shares of the company's common stock on the open market.

It is worth noting that the core product Senapalil was approved for first-line maintenance treatment for all people with ovarian cancer in China in January 2025. Since January 1, 2026, it has been included in the national medical insurance drug catalogue. In the first half of the year, China's sales revenue was 70 million yuan, an increase of 877.8% over the previous year, and commercialization will accelerate this year. The European listing application for Senapali has been accepted and is expected to be approved in the second half of 2026.